Compare Intel Corp (INTC) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Johnson & Johnson — how do they compare? Intel Corp trades at $104.7 (market cap $566.04B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Intel Corp and Johnson & Johnson are close in size by market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Johnson & Johnson for 129 Days on average.
| INTC | JNJ | |
|---|---|---|
Market Cap | $566.04B | $618.09B |
Volume | 118,475,837 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $140.94 | $278.43 |
52-Week Low | $33.62 | $186.00 |
Typical Hold Time | 116 Days | 129 Days |
Enterprise Value | $586.85B | $646.37B |
Dividend Yield | 2.24% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $104.70, down 7.44% over 24 hours, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported three consecutive quarterly EPS beats, though annual revenue declined to $52.85B in 2025 with a net loss of $267M. Intel Foundry's 31% year-over-year growth in Q2 2026 highlights its strategic pivot, while cash flow improved to $6.46B net in 2025.
Intel's turnaround story faces execution risks amid intense competition, but analyst consensus targets $111.72 with 38% buy ratings. Key opportunities include AI infrastructure demand and foundry expansion, balanced by margin pressures and high debt levels. The stock's 222% surge in 2026 reflects optimism, yet profitability remains a challenge.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
